Difficulty: Medium
Average Score: 91%
Practice
Regarding acute asthma exacerbations management, all of the following are false except:
Correct answer
B
Rationale
In the management of acute asthma exacerbations in pediatric patients, it is crucial to understand the appropriate pharmacological interventions to provide prompt and effective care.
Option B is the correct answer because it includes the standard and evidence-based treatments for acute asthma exacerbations in children. Nebulized ╬▓2 agonists help in bronchodilation, systemic corticosteroids reduce inflammation, and ipratropium bromide can further improve bronchodilation.
The other options include incorrect medications or inappropriate combinations for managing acute asthma exacerbations in children. For example, option A includes IV aminophylline, which is not typically recommended in current guidelines due to its narrow therapeutic window and potential for toxicity in pediatric patients.
Option C includes formoterol, which is not typically used in the acute management of asthma exacerbations in children. Methylxanthines like theophylline are also not commonly used due to their narrow therapeutic index and potential for side effects.
Option D includes salmeterol, which is a long-acting ╬▓2 agonist not indicated for acute exacerbations. Theophylline is also not a first-line treatment due to its side effect profile and variable therapeutic response in pediatric patients.
Educationally, understanding the appropriate pharmacological management of acute asthma exacerbations in pediatric patients is essential for nurses and healthcare providers working in pediatric settings. By knowing the correct medications and their indications, dosages, and potential side effects, healthcare professionals can ensure safe and effective care for children experiencing acute asthma exacerbations.
Option B is the correct answer because it includes the standard and evidence-based treatments for acute asthma exacerbations in children. Nebulized ╬▓2 agonists help in bronchodilation, systemic corticosteroids reduce inflammation, and ipratropium bromide can further improve bronchodilation.
The other options include incorrect medications or inappropriate combinations for managing acute asthma exacerbations in children. For example, option A includes IV aminophylline, which is not typically recommended in current guidelines due to its narrow therapeutic window and potential for toxicity in pediatric patients.
Option C includes formoterol, which is not typically used in the acute management of asthma exacerbations in children. Methylxanthines like theophylline are also not commonly used due to their narrow therapeutic index and potential for side effects.
Option D includes salmeterol, which is a long-acting ╬▓2 agonist not indicated for acute exacerbations. Theophylline is also not a first-line treatment due to its side effect profile and variable therapeutic response in pediatric patients.
Educationally, understanding the appropriate pharmacological management of acute asthma exacerbations in pediatric patients is essential for nurses and healthcare providers working in pediatric settings. By knowing the correct medications and their indications, dosages, and potential side effects, healthcare professionals can ensure safe and effective care for children experiencing acute asthma exacerbations.